Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in T

Skip to Content

Clinical Trial Details

EA5163/S1709 INSIGNA

Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Objective

ECOG-ACRIN EA5163

“INSIGNA”

A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

NCT#03793179

IRB Protocol Number
NCT#03793179?

Clinical Trial Categories

  • Lung Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6031